文献速递病毒性肝炎

丙型肝炎病毒控制性人类感染研究的伦理问题

Ethics of Controlled Human Infection Studies With Hepatitis C Virus.
PubMed 文献 · Clin Infect Dis · 2023-01-01

全球消除丙型肝炎病毒(HCV)需有效疫苗,而HCV控制性人类感染(CHI)研究此前未被考虑,直至高效治疗出现。本文依据10项伦理考量评估建立HCV CHI研究项目的伦理问题,结论认为开发HCV CHI模型在伦理上可接受,且应作为全球消除HCV的优先事项。

要点

  • 高效治疗使HCV CHI研究的伦理评估成为必要。
  • 依据10项伦理考量评估HCV CHI模型开发。
  • 结论认为开发HCV CHI模型在伦理上可接受。

核心结论

  • 开发HCV CHI模型在伦理上可接受。
  • 若实施得当,开发该模型应成为全球消除HCV路径上的优先事项。

研究设计与样本

  • 本文为伦理分析,依据10项伦理考量评估建立HCV CHI研究项目的伦理问题。

主要发现

  • HCV CHI研究近期才被考虑,因高效治疗已可及。
  • 故意感染HCV后成功治疗已可行,故必须评估建立HCV CHI研究项目的伦理。

关键数值与推荐

  • 充分的社会价值
  • 合理的风险-获益特征
  • 合适的研究场所选择
  • 公平的参与者选择
  • 稳健的知情同意

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Global elimination of hepatitis C virus (HCV) will be difficult to attain without an effective HCV vaccine. Controlled human infection (CHI) studies with HCV were not considered until recently, when highly effective treatment became available. However, now that successful treatment of a deliberate HCV infection is feasible, it is imperative to evaluate the ethics of establishing a program of HCV CHI research. Here, we evaluate the ethics of studies to develop an HCV CHI model in light of 10 ethical considerations: sufficient social value, reasonable risk-benefit profile, suitable site selection, fair participant selection, robust informed consent, proportionate compensation or payment, context-specific stakeholder engagement, fair and open collaboration, independent review and oversight, and integrated ethics research. We conclude that it can be ethically acceptable to develop an HCV CHI model. Indeed, when done appropriately, developing a model should be a priority on the path toward global elimination of HCV.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rid A, Feld JJ, Liang TJ, et al. Ethics of Controlled Human Infection Studies With Hepatitis C Virus. Clin Infect Dis. 2023. PMID: 37579202. doi:10.1093/cid/ciad382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。